image
XOMA Royalty Corp. XOMA
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 25.6
-2.4 %
$ 306 M
Market Cap
-35.16
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one XOMA stock under the worst case scenario is HIDDEN Compared to the current market price of 25.6 USD, XOMA Royalty Corp. is HIDDEN

XOMA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one XOMA stock under the base case scenario is HIDDEN Compared to the current market price of 25.6 USD, XOMA Royalty Corp. is HIDDEN

XOMA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one XOMA stock under the best case scenario is HIDDEN Compared to the current market price of 25.6 USD, XOMA Royalty Corp. is HIDDEN

XOMA Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart XOMA

image
1M -8%
6M -5%
1Y -13%
3Y 9%
5Y 45%
All
$28.0$28.0$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
28.5 M REVENUE
498.72%
Growth Rates
1Year 498.72%
3Years -9.28%
5Years 9.17%
7Years -8.41%
10Years 4.21%
-40 M OPERATING INCOME
4.47%
Growth Rates
1Year 4.47%
3Years -48.59%
5Years -59.40%
7Years -18.84%
10Years 6.91%
-13.8 M NET INCOME
66.15%
Growth Rates
1Year 66.15%
3Years -23.31%
5Years -47.46%
7Years -9.99%
10Years 9.69%
-13.7 M OPERATING CASH FLOW
24.29%
Growth Rates
1Year 24.29%
3Years -17.11%
5Years -117.11%
7Years -29.53%
10Years 15.97%
-28.3 M INVESTING CASH FLOW
-3874.54%
Growth Rates
1Year -3874.54%
3Years -2.17%
5Years -7.92%
7Years -51.83%
10Years -9.31%
-11.1 M FINANCING CASH FLOW
-9.23%
Growth Rates
1Year -9.23%
3Years -23.13%
5Years -6.42%
7Years -9.10%
10Years -2.76%
15.9 M REVENUE
579.42%
Growth Rates
1Year 498.72%
3Years -9.28%
5Years 9.17%
7Years -8.41%
10Years 4.21%
5.93 M OPERATING INCOME
181.75%
Growth Rates
1Year 4.47%
3Years -48.59%
5Years -59.40%
7Years -18.84%
10Years 6.91%
2.37 M NET INCOME
159.65%
Growth Rates
1Year 66.15%
3Years -23.31%
5Years -47.46%
7Years -9.99%
10Years 9.69%
2.2 M OPERATING CASH FLOW
175.71%
Growth Rates
1Year 24.29%
3Years -17.11%
5Years -117.11%
7Years -29.53%
10Years 15.97%
-6.69 M INVESTING CASH FLOW
81.63%
Growth Rates
1Year -3874.54%
3Years -2.17%
5Years -7.92%
7Years -51.83%
10Years -9.31%
-6.89 M FINANCING CASH FLOW
-546.72%
Growth Rates
1Year -9.23%
3Years -23.13%
5Years -6.42%
7Years -9.10%
10Years -2.76%
Balance Sheet XOMA Royalty Corp.
image
Current Assets 126 M
Cash & Short-Term Investments 105 M
Receivables 17 M
Other Current Assets 3.41 M
Non-Current Assets 95.7 M
Long-Term Investments 0
PP&E 351 K
Other Non-Current Assets 95.3 M
47.53 %7.69 %43.08 %Total Assets$221.3m
Current Liabilities 24.4 M
Accounts Payable 1.05 M
Short-Term Debt 11.4 M
Other Current Liabilities 11.9 M
Non-Current Liabilities 115 M
Long-Term Debt 107 M
Other Non-Current Liabilities 7.62 M
8.18 %8.56 %77.04 %5.47 %Total Liabilities$139.4m
EFFICIENCY
Earnings Waterfall XOMA Royalty Corp.
image
Revenue 28.5 M
Cost Of Revenue 206 K
Gross Profit 28.3 M
Operating Expenses 68.3 M
Operating Income -40 M
Other Expenses -26.2 M
Net Income -13.8 M
30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)28m(206k)28m(68m)(40m)26m(14m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
99.28% GROSS MARGIN
99.28%
Averages
1Year 99.28%
3Years 92.94%
5Years 95.56%
7Years 91.32%
10Years 86.18%
-140.33% OPERATING MARGIN
-140.33%
Averages
1Year -140.33%
3Years -436.26%
5Years -244.12%
7Years -222.84%
10Years -270.56%
-48.52% NET MARGIN
-48.52%
Averages
1Year -48.52%
3Years -396.82%
5Years -220.76%
7Years -199.64%
10Years -236.91%
-16.87% ROE
-16.87%
Averages
1Year -16.87%
3Years -25.56%
5Years -10.03%
7Years -19.81%
10Years 111.94%
-6.25% ROA
-6.25%
Averages
1Year -6.25%
3Years -11.95%
5Years -3.15%
7Years -6.39%
10Years -22.64%
-13.62% ROIC
-13.62%
Averages
1Year -13.62%
3Years -15.21%
5Years -4.55%
7Years -9.65%
10Years -58.73%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis XOMA Royalty Corp.
image
10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -13.8 M
Depreciation & Amortization 216 K
Capital Expenditures -20 K
Stock-Based Compensation 10.3 M
Change in Working Capital -2.79 M
Others -6.4 M
Free Cash Flow -13.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets XOMA Royalty Corp.
image
XOMA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership XOMA Royalty Corp.
image
Sold
0-3 MONTHS
11.6 M USD 3
3-6 MONTHS
15 M USD 1
6-9 MONTHS
948 K USD 2
9-12 MONTHS
0 USD 0
Bought
50.8 K USD 1
0-3 MONTHS
960 K USD 3
3-6 MONTHS
21.7 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif. prnewswire.com - 1 week ago
Collect Up To 11.5% From The Healthcare Sector Make your portfolio income-producing and provide valuable cash for your daily life. Aim to be healthy and have the money you need when emergencies arise. America is getting older. Healthcare income opportunities abound. seekingalpha.com - 2 weeks ago
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) today announced that they have entered into a definitive merger agreement (“the Merger Agreement”), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock (“Turnstone common stock”) plus one non-transferable contingent value right (“CVR”). globenewswire.com - 3 weeks ago
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. zacks.com - 1 month ago
XOMA Royalty Declares Quarterly Preferred Stock Dividends EMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. globenewswire.com - 1 month ago
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD $20 million at closing, with a total transaction of up to USD $30 million. globenewswire.com - 1 month ago
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates XOMA Royalty (XOMA) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.86 per share a year ago. zacks.com - 2 months ago
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025. globenewswire.com - 2 months ago
XOMA Royalty Completes Sale of Kinnate Pipeline Assets XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens globenewswire.com - 3 months ago
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's (TSE:4502/NYSE:TAK) initiation of Phase 3 clinical trial of mezagitamab (TAK-079), identified from BioInvent's proprietary n-CoDeR® antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia (ITP). accessnewswire.com - 3 months ago
XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist XOMA aggregates future biotech royalties and milestone rights for stable, diversified revenue streams. However, I believe its preferred shares (under tickers XOMAO and XOMAP) offer attractive yields with cumulative, perpetual dividends. Since XOMA's diversified portfolio features high-potential, recently FDA-approved assets like Ojemda and Miplyffa, I also think the yields should be relatively secure. seekingalpha.com - 3 months ago
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter at the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025. globenewswire.com - 3 months ago
8. Profile Summary

XOMA Royalty Corp. XOMA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 306 M
Dividend Yield 0.57%
Description XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Contact 2200 Powell Street, EmeryVille, CA, 94608 https://www.xoma.com
IPO Date June 6, 1986
Employees 13
Officers Mr. Thomas M. Burns Senior Vice President of Finance & Chief Financial Officer Mr. Bradley Sitko Chief Investment Officer Mr. Owen P. Hughes Jr. Chief Executive Officer & Director